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Abstract. We used a prospective, open-label randomized trial to evaluate two treatment regimens in Tanzanian
children two months to four years of age presenting to a hospital with a packed cell volume (PCV) < 25%. Treatment
was either standard (14 days of ferrous sulfate and an antimalarial) or extended (three months of ferrous sulfate and
three antimalarial treatments). The prevalence of anemia was measured two weeks after completion of treatment and
six months after recruitment. Two weeks after completing treatment, the prevalence of PCV < 33% was 58% in the
standard treatment arm and 44% in the extended treatment group (P  0.04), and the mean PCV was significantly
higher in the extended treatment arm (32.1%, SD 4.5% versus 30.8%, SD 4.9%; P 0.031). However, there was
no difference in the prevalence of PCV < 25% in the first survey, and the benefits of extended therapy were only
apparent six months after recruitment in children compliant with the extended treatment (odds ratio of PCV < 25%
0.16, P  0.06). Compliance was satisfactory in only 39% (82 of 209) of the children in the first week of treatment.
Extending the duration of therapy and improving compliance may have health benefits for anemic children in malaria-
endemic settings.
INTRODUCTION
More than 103 million children are anemic in Africa alone.1
The public health impact of anemia is probably highest in
malaria-endemic areas, where iron deficiency also tends to be
common. In southern Tanzania, the community prevalence of
anemia2 (packed cell volume [PCV] < 33%) in children less
than five years old was 87% and the annual incidence of
severe anemia (PCV < 25%) was 0.6 episodes per infant.3 In
this setting, anemia is a leading cause of pediatric admission
and inpatient pediatric death, even though blood transfusions
are available. Although the management of anemia is one of
the most frequently encountered clinical problems in sub-
Saharan Africa, surprisingly little information is available on
the effect of frequently used treatment regimens.4–6
The etiology of anemia is frequently multi-factorial, with
the relative contribution of iron deficiency, malaria, hemo-
globinopathies, and intestinal parasitosis (e.g., hookworm)
being different in distinct settings. In Ifakara in southern Tan-
zania, a recent intervention cohort study concluded that iron
deficiency and malaria cause 29% and 60%, respectively, of
severe anemia episodes in infancy.3 Intestinal parasites and
hemoglobinopathies are unlikely to be causes of anemia of
public health relevance in children less than five years old in
this setting.7,8 Thus, the standard approach to anemia treat-
ment with ferrous sulfate and antimalarial seems appropriate,
particularly where access to diagnostic tools is poor. Iron is
often given for two weeks, which is shorter than the recom-
mended treatment of iron deficiency anemia in standard
texts, where treatment is continued for three months after the
hemoglobin level has returned to normal.9 Although this ap-
proach has been encouraged “where possible” by the World
Health Organization and the United Nations Childrens Fund
Integrated Management of Childhood Illness (IMCI),10 the
benefits remain undocumented. Thus, it is possible that many
anemic children living in malarious areas receive inadequate
treatment and their hemoglobin levels do not increase high
into the normal range. Subsequent reinfection with malaria
may depress hemoglobin levels to compromising levels that
require blood transfusion, an unattractive end-result given
the difficulties accessing blood transfusions, the consequences
of a delay in receiving a necessary transfusion,11,12 and the
increasing prevalence of human immunodeficiency virus and
other infectious agents in most sub-Saharan countries.
Given the major contribution of malaria to anemia, it may
be useful to extend the period of protection against Plasmo-
dium falciparum infection beyond that afforded by a single
treatment dose at the start of the anemia treatment regimen.
This will increase the time available for hematologic recovery
before the next P. falciparum insult. Furthermore, although it
is now clear that prophylactic doses ( 2 mg/kg/day) of iron
do not affect risk of malaria,3,13–15 there is a suggestion of an
increased risk of malaria in children receiving treatment doses
of iron.5,16,17 Thus, it is prudent to cover any extended period
of iron treatment with anti-malarial protection.
We report a two-arm randomized comparison of the 14-day
anemia treatment versus an extended three-month regimen of
iron and antimalarials.
MATERIALS AND METHODS
Study area, recruitment, and treatment assignment. The
study was conducted in the semi-urban setting of Ifakara, a
malaria holoendemic area of southern Tanzania described in
detail elsewhere.3,18 Year round malaria transmission causes
clinical cases predominantly in young children. Sulfadoxine-
pyrimethamine (SP) remains efficacious with no late clinical
failures in a recent study.19
The study protocol was reviewed and approved by the ethi-
cal committee of the Ifakara Health Research and Develop-
ment Center’s and the National Medical Research Co-
ordinating Committee of Tanzania. Sick children attending
the Mother and Child Health Clinic or the pediatric ward of
St. Francis Designated District Hospital were eligible if they
had a PCV < 25%, were between two months and five years
of age, were permanent residents of the Ifakara study area,
and had a parent who was able and willing to give written
informed consent. Recruitment started in January 2000 and
was completed in March 2001. Children were excluded if they
met clinical criteria for blood transfusion (i.e., had chest in-
drawing indicating respiratory distress) or if they were in-
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volved in another trial. A recruitment questionnaire docu-
mented demographic characteristics and the PCV, and a thick
blood film was checked for P. falciparum parasitemia. Each
child was allocated the lowest available study number and
assigned the treatment indicated on a card within an opaque
envelope labeled only with the study number, thus concealing
treatment allocation until assignment of the intervention.
Treatments were randomly allocated to study numbers by a
computer program using variable-size block randomization.
The envelopes were prepared at a remote site by someone not
involved in field activities.
Interventions, participant flow, and follow-up. Treatment
doses were assigned on the basis of weight categories: chil-
dren < 10 kg received a half tablet of SP (Shelys Pharmaceu-
ticals, Dar es Salaam, Tanzania, each tablet contained 125 mg
of sulfadoxine and 6.25 mg of pyrimethamine) and half fer-
rous sulfate tablets (30 mg of elemental iron as ferrous sulfate;
West-Coast Pharmaceutical Works, Ahmedabad, India).
Children weighing  10 kg were given whole SP and ferrous
sulfate tablets. The target dose of elemental iron was 4 mg/
kg/day. Children in the standard treatment arm were given a
single dose of SP and 14 days of ferrous sulfate. Children
allocated to the extended treatment were given a single dose
of SP, a 28-day course of ferrous sulfate, and a date to return
one month later, when they were informed that further ane-
mia treatment would be provided. Written instructions rein-
forced this message. At the second visit, a second dose of SP
was administered, an additional 28 days of ferrous sulfate
dispensed and a third date was given, one month later. At the
third visit, the final dose of SP and a third course of 28 days
ferrous sulfate was given. Iron doses were packaged in zip-
lock plastic drug wallets with a pictorial reminder to admin-
ister one dose per day. All doses of SP were supervised.
The follow-up scheme is shown in Figure 1. Compliance
with iron was assessed by pill counts when photo-identity
cards were delivered one week after recruitment, when chil-
dren in the extended treatment arm received doses two and
three of SP, and when all children were invited for the first
cross-sectional survey two weeks after completion of treat-
ment. It was anticipated that compliance with extended treat-
ment might be inadequate. To document this, children were
deliberately not followed-up if they did not attend for subse-
quent doses of SP and iron on time because such follow-up is
likely to enhance compliance. Incomplete compliance data
was considered more desirable than the complete but biased
data that would have resulted from more vigorous follow-up.
All children were invited to the second survey six months
after recruitment. At the cross-sectional surveys, the PCV,
P. falciparum parasitemia, erythrocyte morphology, and
sickle cell status were assessed. Mothers were encouraged to
bring their child to a project clinical officer at the Mother and
Child Health Clinic or St. Francis Designated District Hospi-
tal if the child became unwell, when clinical data were re-
corded on pre-coded questionnaires, thus documenting the
frequency of admission, blood transfusion, episodes of ma-
laria, and outpatient visits. Axillary temperatures were mea-
sured using electronic thermometers.
Blood slides were read according to standard quality con-
trolled procedures.3 Briefly, each slide was read indepen-
dently by two slide readers and a computer program was used
to identify slides with discordant readings, which would then
be read a third time. The PCVs were measured in a micro-
capillary tube after centrifugation and hemoglobin electro-
phoresis was performed on cellulose acetate strips. Microcytic
hypochromic anemia was defined on the basis of erythrocyte
morphology on thin blood film examination and a PCV < 33%.
Data management and statistical analysis. Data were
double entered and cleaned before databases were locked
and the analysis conducted using Stata version 7 (Stata Cor-
poration, College Station, TX) according to a pre-agreed ana-
lytical plan. Anemia was defined as a PCV < 33% and was
considered severe when the PCV was < 25%. A sample size of
150 children in each arm was estimated to provide 80% power
to determine with 95% confidence a reduction of 33% in the
proportion of children with anemia (Epi-Info, Centers for
Disease Control and Prevention, Atlanta, GA). Children
were said to be compliant if they consumed all scheduled
doses of SP and at least 75% of the ferrous sulfate doses. The
FIGURE 1. Schedule of trial events. SP  sulfadoxine-pyrimethamine treatment; Com  compliance assessment; CSV  cross-sectional
survey.
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primary endpoint was based on the proportion of anemic chil-
dren at the first survey, regardless of compliance. The effect
of the interventions on severe anemia was also assessed, and
both endpoints were evaluated at the second survey. Odds
ratios (ORs) were calculated using logistic regression and the
protective effect defined as (1 − OR). The effect on the inci-
dence of presentation to hospital and of blood transfusion was
also evaluated. The analyses were repeated including only
compliant children.
RESULTS
A total of 311 children were recruited. Completeness of
follow-up was similar in the two arms (Figure 2), as was the
time between recruitment and withdrawal or death. The
groups were comparable at recruitment (Table 1), with a
mean PCV of 21.4% (SD  2.6) in the standard treatment
arm and 21.5% (SD  2.6) in the extended treatment arm.
Two weeks after completing anemia treatment, the preva-
lence of anemia was 58% in the standard treatment arm and
44% in the extended treatment group, with a significant pro-
tective effect of 42% (Table 2). Similarly, the mean PCV was
higher in children receiving the extended treatment than in
those receiving the standard treatment (32.1%, SD  4.5%
versus 30.8%, SD 4.9%; P 0.031). The mean increase in
PCV also tended to be higher in children receiving the ex-
tended treatment (10.2%, SD  5.7% versus 8.9%, SD 
5.9%; P 0.082). The two groups had a similar prevalence of
severe anemia in the first survey, and only one child, in the
standard treatment arm, had a PCV < 15%. At the second
survey, the prevalence of anemia was similar in the two
groups. However, those who complied with the extended
treatment tended to have less severe anemia than those com-
pliant with the standard treatment (P  0.06).
There were no differences in the incidence of attendance to
outpatients, admission, blood transfusion, or clinical malaria
between the two groups (Table 3). The prevalences of hypo-
chromic, microcytic anemia and P. falciparum parasitemia
were also similar in the two groups in both cross-sectional
surveys (Table 4).
The pattern of compliance varied during the treatment
course. Overall compliance, assessed two weeks after treat-
ment should have been completed, was 87% (108 of 124) in
the standard treatment arm. In the extended arm, 55% (85 of
154) of the children received two or more doses of SP, and
44% (68 of 154) received all three doses. All children who
received three doses of SP and who also had complete com-
pliance data (n  39) had good overall compliance to iron.
One week after treatment started, compliance was satisfac-
tory in only 39% (82 of 209) of the children: 22% (47 of 209)
were poor compliers and 38% (80 of 209) had over-consumed
iron, and 12% (26 of 209) were taking more than twice the
expected dose. Over-consumption was particularly marked in
the extended treatment arm in which a week after the start of
treatment, 21% (22 of 103) had consumed at least twice the
expected amount of iron and 2% (2 of 103) had consumed
more than four times the expected amount of iron.
DISCUSSION
We conducted a randomized trial comparing a standard
14-day anemia treatment with an extended, three-month regi-
FIGURE 2. Trial profile. CSV  cross-sectional survey.
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men. The prevalence of severe anemia in the standard treat-
ment arm decreased from 100% at recruitment to 10% two
weeks after completing treatment, and this effect was main-
tained six months after recruitment. However, at least half the
children receiving the standard treatment remained anemic in
each survey. In the extended treatment arm, 44% of the chil-
dren were anemic shortly after completing treatment, which is
equivalent to a 42% protective effect compared with the stan-
dard regimen. Although this benefit may have been partly
due to the increased time available for children in the ex-
tended treatment arm for recovery from acute, malaria-
induced anemia, rather than an enhanced efficacy of the drug
regimen, this would not have been the case in the second
survey. Some analyses, in particular those confined to good
compliers, were based on small numbers and many of the
endpoints failed to reach statistical significance. Nevertheless,
children in the extended arm were less anemic at both cross-
sectional surveys, with confidence intervals for the various
effect estimates overlapping each other. In particular, chil-
dren compliant with the extended regimen were 84% less
likely (P  0.06) to have severe anemia six months after the
initial diagnosis. Taken together, these findings are consistent
with a favorable effect of the extended treatment, although
this regimen still produced results that were far from satisfac-
tory.
The importance of P. falciparum infection in the pathogen-
esis of anemia in this setting is underlined by the 68% preva-
lence of parasitemia at recruitment, which is much higher
than that found in other cohorts from the same area.18,20
Many of the children recruited may have had a PCV slightly
more than 25% before their P. falciparum infection and be-
came severely anemic as an acute result of their parasitiza-
tion. This might tempt some to stop treating anemic children
with iron in such settings.21 However, this ignores the diffi-
culties of distinguishing anemia due to malaria from that due
to iron-deficiency, especially in resource-poor settings. The
implications of not adequately treating an anemic child in a
malaria-endemic setting are potentially grave, whereas iron
treatment is relatively safe. Furthermore, there is clear evi-
dence of a benefit of treating children with severe malarial
anemia with iron,4 although this should be done in conjunc-
tion with antimalarial treatment.5
There are major gaps in the evidence base for anemia treat-
ment in African children. First, what should be the PCV
threshold for treatment? Children recruited to this study had
a PCV < 25%, which is similar to the 27% cut-off adopted by
the IMCI.10 Why the threshold for treatment in Africa is set
lower than in the west is not clear, especially since anemic
children living in malaria-endemic settings are presumably at
higher risk of serious illness or death than anemic children in
non-endemic settings. However, the accurate assessment of
the burden of anemia is complicated by technical and ethical
concerns. Second, we were able to find only one randomized
study of iron and antimalarial use in the treatment of anemia6,
which questions the basis for the treatment recommendations
for this very common problem.
Assessments of compliance with iron were based on tablet
counts and may therefore be inaccurate if tablets were not
TABLE 1
Baseline comparability*
Variable
Treatment group
Standard Extended
n/N % n/N %
Male sex 82/157 52 73/154 47
Age category, 2–12 41/157 26 35/154 23
months 13–24 44/157 28 40/154 26
25–60 72/157 46 79/154 51
Malnutrition None 73/155 47 74/152 49
Mild 62/155 40 58/152 38
Moderate 17/155 11 16/152 11
Severe 3/155 2 4/152 3
Distance (km) 0–1.59 56/157 36 52/154 34
home-SFDDH 1.6–3.09 52/157 33 47/154 31
3.1 49/157 31 55/154 36
Blood slide positivity 107/151 71 95/146 65
Mosquito net use
(CSV1)
96/137 70 77/105 73
Hemoglobin trait AA 114/150 76 118/149 79
AF 19/150 13 18/149 12
AS 9/150 6 10/149 7
FS 3/150 2 1/149 1
SS 5/150 3 2/149 1
Iron compliance < 75% 29/106 27 18/103 17
after 1 week 75–125% 43/106 41 39/103 38
> 125%† 34/106 32 46/103 45
* SFDDH  St. Francis Designated District Hospital; CSV1  cross-sectional survey 1.
† Iron compliance > 125% reflects the frequency of over-consumption of iron 1 week after
the start of treatment.
TABLE 2
Effect of standard and extended anemia treatment regimens*
Analysis
Treatment arm
OR 95% CI Protective effect
Standard Extended
n/N % n/N %
All recruited children
PCV < 33% survey 1 78/135 57.8 48/108 44.4 0.58 (0.35–0.97) 42%†
PCV < 25% survey 1 14/135 10.4 8/108 7.4 0.69 (0.29–1.68) 31%
PCV < 33% survey 2 61/122 50.0 62/122 50.8 1.03 (0.63–1.70) −3%
PCV < 25% survey 2 12/122 9.8 7/122 5.7 0.55 (0.21–1.40) 45%
Compliant children
PCV < 33% survey 1 40/67 59.7 17/39 43.6 0.52 (0.24–1.15) 48%
PCV < 25% survey 1 7/67 10.5 3/39 7.7 0.71 (0.19–2.72) 29%
PCV < 33% survey 2 37/65 56.9 17/37 46.0 0.64 (0.29–1.44) 36%
PCV < 25% survey 2 9/65 13.9 1/37 2.6 0.16 (0.00–1.06) 84%‡
* OR  odds ratio; CI  confidence interval; PCV  packed cell volume.
† P  0.04.
‡ P  0.06.
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consumed by the intended recipient but either wasted or
taken by someone else. However, more stringent approaches
to the assessment of compliance are fraught with difficulties
because all biochemical markers of iron status are affected by
acute infections, including P. falciparum.22–24 According to
our compliance assessments, over-consumption of iron may
become a cause for concern. The risk of toxicity increases as
the dose of elemental iron increases: doses more than 30 mg/
kg are potentially toxic and doses in excess of 180 mg/kg are
potentially fatal.25 Our target dose of elemental iron was 4
mg/kg/day. Thus, a 7.5- or > 45-fold over-consumption would
be required to fall into the potentially toxic and potentially
fatal categories, respectively. It seems unlikely that any of the
children over-consuming iron in our study would have expe-
rienced serious adverse effects as a result. Nevertheless, the
smallest child recruited weighed 4.1 kg; had she been random-
ized to the extended treatment arm and consumed the entire
28-day course at once, she would have received the equivalent
of 185 mg/kg, a dangerous overdose.
Compliance was poor despite the fact that the drugs were
dispensed with clear instructions to sick children in a trial
setting. Less than half the children in the extended treatment
arm received all intended doses of SP. The trial was deliber-
ately conducted so that the likelihood of altered compliance,
simply by virtue of being in the trial, was minimized. Thus, the
patterns of compliance documented are likely to reflect those
in real life and as such give cause for concern. Various strat-
egies to improve compliance have been explored. Some have
focused on changing the formulation of iron to try and reduce
the incidence of side effects, which are thought to contribute
to poor compliance.26,27 Other factors known to affect com-
pliance include the motivation of those dispensing the drug,
its perceived safety and efficacy, its presentation, and the
complexity of the dosing regimen.28–32 Finally, although hith-
erto unproven, it seems likely that inviting patients to return
for a follow-up appointment, as recommended by the IMCI,10
might also improve compliance.
In conclusion, health benefits are likely to result from im-
proved compliance to anemia and other treatments in chil-
dren living in malaria-endemic settings. Extending the period
of antimalarial and iron treatment of anemic children in
Ifakara improved outcome: even though compliance was
poor, the effects in those who complied were marked. This
study does not provide definitive information to guide policy
makers, but underlines the need for further work on this im-
portant topic. It would be useful to establish a rational thresh-
old for anemia treatment, to assess the efficacy of alternative
anemia treatment regimens, and to develop ways of improv-
ing compliance to treatment, and thus to establish an evi-
dence-base for practical anemia treatment in Africa.
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